Market Intelligence, Clinical Progress, and High-Purity Reagents for Gastrointestinal Malignancy Development.
CDH17 (Cadherin-17, UniProt Q12864) is a membrane glycoprotein containing three cadherin domains (Cadherin 1, 2, 3) that mediates calcium-dependent cell adhesion. It is highly expressed in gastrointestinal (GI) malignancies such as gastric and colorectal cancers, with restricted expression in normal tissues, making it an attractive target for antibody-drug conjugates (ADCs), bispecific T-cell engagers, CAR-T therapy, and diagnostic imaging. Key naturally occurring mutations include rs2243518, rs1131829, and rs1051623 (dbSNP), which may influence protein function or immunogenicity.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CDH17 drug discovery.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CDH17 ECD-Fc Fusion Protein & Mutant Variants. Human, Mouse, Cynomolgus orthologs & mutant forms (e.g., rs2243518). HEK293 expressed (mammalian glycosylation). High purity (>95%), endotoxin <1 EU/µg. Sequence verified. | View CDH17 Products |
| Gene Delivery | CDH17 Promise-ORF / Lentivirus Premade Particles. Full-length human CDH17 ORF for stable cell line construction. Ideal for flow cytometry and internalization assays. | View CDH17 Products |
| Benchmark Ab | Anti-CDH17 (Investigational Reference / Biosimilar Sequence). Recombinant positive control for binding and affinity assays. Sequence verified. | View CDH17 Products |
| Validator | CDH17 siRNA Set (3 unique target-specific sequences). For knockdown verification and specificity controls in cell-based assays. | View CDH17 Products |
| Related Target: CDH1 (E-Cadherin) | E-Cadherin / CDH1 ECD Protein. Essential for cadherin subfamily counter-screening and off-target safety evaluation. | View CDH1 Products |
| Related Target: CEACAM5 (CEA) | CEACAM5 ECD-Fc Protein. Co-expressed in GI adenocarcinomas; relevant for combination therapy and dual-targeting strategies. | View CEACAM5 Products |
| Related Target: CLDN18.2 | CLDN18.2 Protein. Synergistic target for gastric cancer combination therapies and bispecific approaches. | View CLDN18.2 Products |
| Related Target: GUCY2C | GUCY2C Protein. Parallel gastrointestinal biomarker for bispecific and multi-target strategies. | View GUCY2C Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse preclinical evaluation | Human / Mouse / Cynomolgus CDH17 ECD-Fc ortholog proteins available with >95% purity; sequence alignment verified for epitope conservation. |
| Cadherin subfamily counter-screening (CDH1, CDH2 off-target liability) | Homolog panel proteins (CDH1, CDH2) sequence-verified; identity mapped across EC domains for epitope liability assessment. |
| Glycosylation-dependent epitope recognition | HEK293 expressed (native glycosylation) with >95% purity; preserves complex glycan structures critical for conformation-dependent binding. |
| Internalization, membrane presentation & conformation-dependent binding assays | Full-length CDH17 lentivirus for stable cell lines; preserves native membrane conformation and glycosylation. Suitable for CAR-T and internalization screens. |
| Lack of assay controls for novel ADC/bispecific/CAR-T programs | Investigational benchmark antibody sequences included as recombinant positive controls; biosimilar reference antibodies also available. |
| False positives in binding ELISA / SPR | Sequence-verified CDH17 siRNA included for target-specificity knockdown confirmation; validated siRNA set (3 unique sequences) for rigorous controls. |
Live CDH17 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CDH17 (Cadherin-17) therapeutics is intensifying, with major players shifting focus from traditional mAbs to Antibody-Drug Conjugates (ADCs), bispecific T-cell engagers, and CAR-T cell therapies. As an essential target in gastrointestinal (GI) malignancies, particularly gastric and colorectal cancers, CDH17 offers highly restricted normal tissue expression, minimizing on-target off-tumor toxicity. First-generation therapies are entering preclinical and early clinical stages, while next-wave R&D targets epitope-engineered biologics with improved tumor-to-normal tissue differentiation, optimal affinity tuning for solid tumor penetration, and combination strategies with immune checkpoint inhibitors or other GI targets (CLDN18.2, CEACAM5, GUCY2C). The pipeline is increasingly focused on ADCs (about 40%) and CAR-T (about 50%), with bispecifics and diagnostic imaging also gaining traction.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Boehringer Ingelheim, Biotheus, Emerging biotech & large pharma | Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma | Internalization Assay (Need high-purity ECD-Fc for coated-pulse experiments); Off-target safety panel (Need CDH1/CDH2 homologs); Cross-species orthologs for preclinical PK/PD. |
| Bispecific (e.g., CDH17xCD3) | Immunotherapy-focused developers, Various biotech | Advanced GI Malignancies, Neuroendocrine Tumors | Cell-line construction (Need CDH17 lentivirus for stable overexpression); Cross-reactivity assay (Human/Cyno/Mouse orthologs); Heterodimer validation (Need cross-reactive Abs). |
| CAR-T / Cell Therapy | Chimeric Therapeutics (UPenn origin), Academic/industry groups | Metastatic Colorectal Cancer, Gastric Cancer | Stable target cell lines (Lentivirus-transduced tumor lines); Knockdown validator (siRNA for specificity); Membrane-presented antigen for CAR binding screens. |
| Diagnostic / Companion Imaging | Molecular imaging collaborators | GI Cancer Staging | High-affinity reference antibody; ECD protein standards for assay calibration and imaging probe development. |
CDH17 Molecular Features
Based on UniProt Q12864, CDH17 contains three extracellular cadherin domains (Cadherin 1, residues 56-156; Cadherin 2, residues 169-270; Cadherin 3, residues 282-383), a transmembrane region (residues 409-429), and a cytoplasmic tail. Known single-nucleotide polymorphisms include rs2243518 (missense), rs1131829 (missense), and rs1051623 (missense), which may affect protein stability or epitope presentation. These features are critical for designing antibodies with selective domain binding and for understanding potential immunogenicity in clinical development.